IRIS

Allergic rhinitis (AR) is one of the most common diseases and represents a global health problem, currently affecting up to 30% of the general population, with a continuously increasing prevalence and significant comorbidities and complications. To date, the mainstay of current treatment strategies of AR includes allergen avoidance, pharmacotherapy and allergen-specific immunotherapy, as defined by Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for both adults and children. The aim of this review is to provide an update on all emerging and future therapeutic options for the treatment of AR.

Emerging and future therapies for allergic rhinitis

LICARI, AMELIA;MARSEGLIA, ALESSIA;MARSEGLIA, GIAN LUIGI
2015-01-01

Abstract

Allergic rhinitis (AR) is one of the most common diseases and represents a global health problem, currently affecting up to 30% of the general population, with a continuously increasing prevalence and significant comorbidities and complications. To date, the mainstay of current treatment strategies of AR includes allergen avoidance, pharmacotherapy and allergen-specific immunotherapy, as defined by Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for both adults and children. The aim of this review is to provide an update on all emerging and future therapeutic options for the treatment of AR.
2015
Pharmacology & Toxicology includes all aspects of pharmacology, toxicology, and pharmaceutics. Of particular importance are cellular and molecular pharmacology, drug design and metabolism, mechanisms of drug action, drug delivery, natural products, xenobiotics, and clinical therapeutics. Toxicology coverage considers cellular and molecular effects of harmful substances, environmental toxicology, occupational exposure, and clinical toxicology. Drug bulletins, drug updates, and pharmaceutical newsletters are excluded as are resources on pharmaceutical engineering. Medicinal chemistry, or synthesis and chemical analysis of pharmaceuticals are placed in the Chemistry & Analysis category.
JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS
2-s2.0-84985942561
Esperti anonimi
Inglese
Internazionale
ELETTRONICO
29
2 Suppl 1
38
46
9
26634586
allergic rhinitis, pharmacotherapy, immunotherapy, omalizumab
no
8
info:eu-repo/semantics/article
262
Licari, Amelia; Marseglia, Alessia; Caimmi, S; Ricci, A; Rundo, B; Poddighe, D; Verrotti, A; Marseglia, GIAN LUIGI
1 Contributo su Rivista::1.1 Articolo in rivista
none
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1176920
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? ND
social impact